Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Biotecnología

Ms. Jennifer  Freiling

Director of Communications

Mr. Ryan  Barrett

Senior Vice President, Gen. Counsel & Company Sec.

Mr. Gregory L. Weaver CPA, M.B.A.

Non-Employee Advisor

Mr. Aaqil  Anwar

Mang. of Corporation Fin. & Investor Relations

Ms. Madison  Crawford

Senior Mang. of Accounting

Mr. Christian  Angermayer

Founder & Chairman of the Supervisory Board

Mr. Florian  Brand

Co-founder & Chief Executive Officer

Dr. Srinivas G. Rao M.D., Ph.D.

Co-Founder & Chief Scientific Officer

Mr. Stephen B. Bardin

MD & Chief Financial Officer

Mr. Frank  Stegert

Vice President of Investment & Venture Management

Ms. Anne  Johnson

Chief Accounting Officer

Gen. Counsel & Corporation Sec.

Dr. Rolando  Gutierrez-Esteinou M.D.

Chief Medical Officer

Dr. Sahil V. Kirpekar M.D.

Chief Bus. Officer

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
Exopharm Limited	0M
Yunnan Botanee Bio-Technology Group Co.LTD	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M

Atai Life Sciences N.V.

Atai Life Sciences N.V. Lista de competidores

Principales competidores